Veritas In Silico

November 2nd, 2026

Company Name: Veritas In Silico Inc.
Representative: Shingo NAKAMURA,
Representative Director and CEO
Listed on: TSE Growth
Stock Ticker Code: 130A
Contact : Tsuneo GODA,
Executive Officer, General Manager,
Corporate Planning Division
Email: ir@veritasinsilico.com

Syntara and Veritas In Silico sign MoU to Accelerate Joint Discovery Research for mRNA-Targeted Compounds

Syntara Limited (Headquarters: ABN 75 082 811 630; Unit 2, 20A Rodborough Road Frenchs Forest, New South Wales, 2086 Australia, hereinafter referred to as "Syntara") and Veritas In Silico Inc. (Headquarters: Shinagawa-ku, Tokyo; Representative Director and CEO: Shingo NAKAMURA, hereinafter referred to as "the Company") hereby announces that it has entered into a joint discovery research to discover mRNA-targeted compounds and have completed the execution of a memorandum of understanding (hereinafter referred to as “the MoU”).

The collaborative research aims to create mRNA-targeted small-molecule drugs at the forefront of global innovation by combining Syntara’s chemical synthesis technologies and strong drug-discovery capabilities — developed by a mid-sized publicly listed Australian biotechnology company — with VIS’s AI-driven mRNA-targeted drug discovery platform, aibVIS, and cellular assay technologies. The parties will complement one another by leveraging their respective areas of expertise. The parties intend to monetize the research outcomes through the joint out-licensing to third parties of novel mRNA-targeted small-molecule therapeutics that may be discovered in the future.

Syntara first became interested in VIS’s technology after reading a paper by VIS published in the scientific journal “*ACS Chemical Biology”*, which led to exchanges between researchers from the two companies. The parties subsequently held a series of discussions regarding the scope and other details of the collaborative research, culminating in the execution of the MoU.

VIS aims to transform itself into a pharmaceutical company in the 2030s and anticipates building a portfolio of multiple pipelines at various stages of development. While pursuing the creation of a range of pipeline candidates with due regard to capital efficiency, VIS will also advance this collaborative research.

Please refer to the following page for the joint announcement by Syntara and VIS regarding this collaborative research.

● Impact on Financial Condition and Business Performance

The execution of the MoU qualifies as the conclusion of a “New Agreement,” a KPI under VIS’s growth strategy, and represents the first of the two new agreements targeted for execution in fiscal 2026 (the fiscal year ending December 31, 2026). As no upfront payments will be made in connection with the MoU, there is no change to the earnings forecast for the fiscal year ending December 31, 2026, announced on February 12, 2026.

The outcomes of this collaborative drug discovery research are expected to contribute to the enhancement of the VIS’s corporate value over the medium to long term, as research and development and commercialization progress.

In case any material matters requiring disclosure arise in the future, it will be promptly disclosed.

END

For Further Information, Contact:

● Veritas In Silico Website Inquiry Form : https://www.veritasinsilico.com/en/contact/

(Joint Announcement by Syntara and VIS)

November 2, 2026

Syntara Limited, and Veritas In Silico Inc. sign MoU to accelerate Discovery of Next-Generation RNA-Binding Chemical

Syntara Limited of ABN 75 082 811 630 Unit 2, 20A Rodborough Road Frenchs Forest NSW 2086 Australia (**Syntara**) and **Veritas In Silico Inc.** of 1-11-1 Nishigotanda, Shinagawa-ku, Tokyo 141-0031, Japan (**VIS**) announced the signing of a Memorandum of Understanding (MoU) to collaborate for the discovery, development, and eventual commercialization of new drugs. The collaboration brings together VIS's advanced AI-driven RNA design platform with Syntara's drug development capabilities.

Under the MoU, the teams aim to generate high-value experimental data, deepen understanding of structure–activity relationships for RNA recognition, and define design criteria that can inform future programs.

Gary Phillips, CEO of Syntara comments, "Syntara's drug development capability, built and applied over several years, has resulted in a pipeline of small molecule drugs in diseases driven by inflammation and fibrosis. I'm excited to see the value we can unlock by collaborating with Veritas In Silico's RNA design platform."

Shingo Nakamura, CEO and Founder of Veritas In Silico comments, "Combining our AI-powered platform with Syntara's drug development capability creates a powerful engine to evaluate and mature novel RNA-binding scaffolds. We look forward to the scientific insights and collaboration opportunities this work can enable."

Based on outcomes, the parties may explore future partnering, licensing or co-development opportunities with biotech and pharmaceutical companies.

END